- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產品
- 聯(lián)系我們
別名: KY 12420, SL-2052, BRN 0067676, NSC 627609 中文名稱:渥曼青霉素
Wortmannin是一種首次命名的PI3K抑制劑,在無細胞試驗中IC50為3 nM,對 PI3K 家族的選擇性較低。Wortmannin 可抑制自噬體的形成,并有效抑制DNA-PK/ATM,在無細胞試驗中IC50為16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。
Wortmannin Chemical Structure
CAS: 19545-26-7
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
MDA-MB-231 | Function assay | 1 to 10 uM | 24 hrs | Inhibition of PI3K in human MDA-MB-231 cells assessed as inhibition of AKT phosphorylation at 1 to 10 uM after 24 hrs by Western blot analysis | 24828286 |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by SRB method, IC50 = 11.4 μM. | 18630894 | |
A549 | Function assay | Inhibition of Plk3 in human A549 cells assessed as casein substrate phosphorylation by Western blot, IC50 = 0.22 μM. | 17135248 | ||
HeLa | Function assay | Binding affinity for Phosphatidylinositol 3-kinase isolated from HeLa cells; Range is 20-120, Ki = 0.12 μM. | 15658870 | ||
HeLa | Function assay | Binding affinity for DNA dependent protein kinase isolated from HeLa cells; Range is 20-120, Ki = 0.12 μM. | 15658870 | ||
HeLa | Function assay | Inhibition of AX-7503 binding to recombinant Plk3 expressed in HeLa cells by Western blot, IC50 = 0.049 μM. | 17135248 | ||
Sf9 | Function assay | Inhibition of human PI3Kalpha expressed in Sf9 cells by fluorescent polarization assay, IC50 = 0.012 μM. | 21121631 | ||
M059J | Function Assay | 12.5 mM | 0.5 h | abolishes the Ser473/Thr308?phosphorylation of AktPKB? | 16227394 |
AT5BIVA | Function Assay | 12.5 mM | 0.5 h | abolishes the Ser473/Thr308?phosphorylation of AktPKB? | 16227394 |
MRC5VI | Function Assay | 12.5 mM | 0.5 h | abolishes the Ser473/Thr308?phosphorylation of AktPKB? | 16227394 |
HeLa | Function Assay | 100?nM? | 1 h | alters the morphology of the transferrin recycling compartment | 16890915 |
SMMC-7721 | Apoptosis Assay | 200?nM | 24 h | increases CHX-induced apoptosis | 17557191 |
MHG-U1 | Growth Inhibition Assay | 10?μM | 24 h | decreases the proportion of G2/M cells | 18787832 |
RT112? | Growth Inhibition Assay | 10?μM | 24 h | decreases the proportion of G2/M cells | 18787832 |
SW1990 | Function Assay | 0.01-1 μM | 1 h | inhibits HA-induced Akt phosphorylation | 19469020 |
Namalwa | Apoptosis Assay | 0.25-1.25 μM | 24/48 h | induces cell apoptosis in both time- and dose- dependent manner | 19757185 |
Jurkat | Apoptosis Assay | 0.25-1.25 μM | 24/48 h | induces cell apoptosis in both time- and dose- dependent manner | 19757185 |
Namalwa | Growth Inhibition Assay | 0.25-1.25 μM | 24/48 h | inhibits cell proliferation in both time- and dose- dependent manner | 19757185 |
Mel-HO-TS | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
A459 | Growth Inhibition Assay | 2.5 μM | 1-4 d | enhances cell growth inhibition treatment with | 25490383 |
H1703 | Growth Inhibition Assay | 2.5 μM | 1-4 d | enhances cell growth inhibition treatment with | 25490383 |
HUVECs | Cytotoxicity Assay | 100 nM | 24 h | attenuates the abrogative effects of calycosin on VRI-induced cytotoxicity | 25450186 |
MDA-MB-231 | Apoptosis Assay | 1?μM? | 48 h | decreases the cell survival treated with 25 μM of F1 or F2 ? | 25300932 |
MCF7 | Function Assay | 100 nM | 24 h | eliminates E2-induced ARE-Luc activity | 25172557 |
MO59K? | Cytotoxicity Assay | 5?μM | 7 d | enhances the cytotoxicity of or | 24953561 |
MO59J | Cytotoxicity Assay | 5?μM | 7 d | enhances the cytotoxicity of or | 24953561 |
MO59K? | Apoptosis Assay | 10 μM | 24 h | increases the DSB level induced by or | 24953561 |
MO59J | Apoptosis Assay | 10 μM | 24 h | increases the DSB level induced by or | 24953561 |
HepG2 | Function Assay | 100 nM | 0.5 h | blocks MA-induced Akt phosphorylation | 24863350 |
A549? | Growth Inhibition Assay | 3 μM? | 2 h | suppresses Akt and GSK3β activation, S-phase arrest, cell apoptosis and caspase-3 activation | 24847863 |
A549? | Function Assay | 10?μm? | 16 h | modulates the IAV replication and causes retention of NP in the nucleus. | 24802111 |
H520 | Function Assay | 10?μM | 1 h | decreases cellular phospho-AKT protein levels | 24447935 |
H1975 | Function Assay | 10?μM | 1 h | decreases cellular phospho-AKT protein levels | 24447935 |
MG-63 | Apoptosis Assay | 10 μM | 12 h | enhances DP-induced apoptosis | 24358301 |
5637 | Apoptosis Assay | 10?μM | 40 min | reverses p21WAF1 expression, CDK expression, and cell inhibition induced by fucoidan | 24333868 |
HEK-293 | Function Assay | 150nM | 16 h | decreases CRT activity | 24324366 |
BEL/FU | Function Assay | 1 mM | 24 h | decreases protein levels of the PI3K/Akt pathway | 24232099 |
A-375 | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
Huh7? | Function Assay | 3?μM | 1 h | reduces the virus entry into the cells | 24184196 |
A-375-TS? | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
GM00637 | Function assay | 1 uM | Inhibition of recombinant Plk3 expressed in human GM00637 cells at 1 uM assessed as decrease in p53 serine-20 phosphorylation | 17135248 | |
Jurkat? | Kinase Assay | IC50 of 24 nM | 15664519 | ||
N2a | Apoptosis Assay | 0.1-10 μM | 2 h | induces decreased cell viability in a concentration-dependent manner | 15842767 |
HeLa | Function Assay | 12.5 mM | 0.5 h | abolishes the Ser473/Thr308?phosphorylation of AktPKB? | 16227394 |
SMMC-7721 | Function Assay | 200?nM | 24 h | up-regulates β1,4GT1 expression | 17557191 |
K562 | Growth Inhibition Assay | 24 h | IC50=25±0.14 nM | 19662361 | |
Jurkat | Growth Inhibition Assay | 0.25-1.25 μM | 24/48 h | inhibits cell proliferation in both time- and dose- dependent manner | 19757185 |
MDA-MB-231 | Function Assay | 400 nM | 4 h | decreases MMP-9 and IL-8 protein in a dose-dependent manner | 22906259 |
MDA-MB-231 | Function Assay | 0–400 nM | 4 h | suppresses Akt phosphorylation in a dose-dependent manner | 22906259 |
Mel-2a | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
MeWo | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
APRE-19 | Apoptosis Assay | 5 μM | 24 h | abolishes FLZ-mediated pro-survival/anti-apoptosis activity | 25329617 |
HT-29? | Growth Inhibition Assay | 1.5?μM | 96 h | decreases cell growth which can be inhibited by KYNA | 25012123 |
SK-N-LO | Function Assay | 100 nM | 0.5 h | decreases the stimulant effects of on Akt phosphorylation | 24654606 |
HL-60 | Function Assay | 0.1?μM | 72 h | blocks cell differentiation | 24607273 |
HepG2? | Function Assay | 200 nM | 0.5 h | attenuates FoxO phosphorylation | 24535192 |
SW480? | Function Assay | 150nM | 20 h | reduces cellular accumulation of β-catenin | 24324366 |
HepG2 | Function Assay | 100 nM | 24 h | attenuates the colonies of the tumor cells with upregulation of Akt1 | 24297510 |
HCT 116? | Function Assay | 100 nM | 24 h | attenuates the colonies of the tumor cells with upregulation of Akt1 | 24297510 |
Mel-HO | Apoptosis Assay | 4/8 μM | 24 h | enhances TRAIL-induced apoptosis? | 24113173 |
HeLa | Function assay | 100 nM | 10 mins | Inhibition of PI3K in human HeLa cells assessed as reduction in EGF-stimulated AKT phosphorylation at S473 at 100 nM preincubated for 10 mins followed by EGF stimulation measured after 5 mins by Western blot analysis | 30380865 |
HeLa | Function assay | 100 nM | 10 mins | Inhibition of PI3K in human HeLa cells assessed as reduction in EGF-stimulated AKT phosphorylation at T308 at 100 nM preincubated for 10 mins followed by EGF stimulation measured after 5 mins by Western blot analysis | 30380865 |
點擊查看更多細胞系數(shù)據(jù) |
產品描述 | Wortmannin是一種首次命名的PI3K抑制劑,在無細胞試驗中IC50為3 nM,對 PI3K 家族的選擇性較低。Wortmannin 可抑制自噬體的形成,并有效抑制DNA-PK/ATM,在無細胞試驗中IC50為16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | 鈣或肽底物不影響Wortmannin對MLCK的抑制,但高濃度的ATP會減弱此種抑制。Wortmannin直接與MLCK催化結構域相互作用,導致不可逆轉的酶活性減弱。Wortmannin對cAMP依賴蛋白激酶,cGMP依賴的蛋白激酶,鈣調蛋白依賴激酶II,和蛋白激酶C均無抑制作用。[1] Wortmannin抑制由fMLP誘導的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50為5 nM 。在人中性粒細胞中,Wortmannin劑量為100 nM時可發(fā)揮完全抑制作用,增加PtdInsP2水平,且對PtdInsP和 PtdIns沒有影響;Wortmannin可動態(tài)調控F-actin水平對fMLP刺激的肌動蛋白聚合無影響。[2] 在RBL-2H3細胞中,Wortmannin通過結合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50為3 nM)對,對Pi4-kinase沒有影響。Wortmannin也抑制Fc epsilon RI介導的組胺分泌和白三烯釋放,對酪氨酸激酶Lyn無影響。[3] 在大鼠脂肪細胞中,劑量為0.1 μM的 Wortmannin可完全抑制胰島素誘導的己糖吸收,二不影響異丙腎上腺素刺激的脂肪分解活性。[4] 在人臍靜脈內皮細胞中,在IGF-1的存在下,Wortmannin抑制胰島素誘導一氧化氮生產,IC50為500nM。[5] 在中國倉鼠卵巢細胞中, Wortmannin以50 μM劑量可抑制DNA雙鏈斷裂(DSB)修復,但對DSB水平無影響或單鏈斷裂(SSB)酶活無影響。Wortmannin可加強電離輻射(紅外)誘導的細胞毒作用,但本身無毒性。[6] Wortmannin抑制水球樣激酶(PLK 1)活性,IC 50為24nM,造成細胞G 2 / M阻滯。[7] 在人巨噬細胞中,Wortmannin增加 Toll樣受體(TLR)介導的白細胞介素- 6的積累,EC 50 = 50 nM。在小鼠巨噬細胞中,Wortmannin顯著增強TLR誘導一氧化氮合酶(iNOS)的表達和亞硝酸鹽積累。Wortmannin激活核因子-κB和上調細胞因子mRNA量。[8] Wortmannin也抑制水球樣激酶(PlK)1和PlK 3,在有絲分裂中發(fā)揮重要作用。Wortmannin治療可能導致可減少由DNA損傷誘導的p53絲氨酸20位磷酸化。[9] 在SW 1990細胞中,Wortmannin可抑制透明質酸誘導Akt磷酸化和細胞運動/遷移。[10] |
|||
---|---|---|---|---|
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3 | 25344912 | ||
Immunofluorescence | DNMT1 | 24001151 | ||
Growth inhibition assay | Cell viability | 25344912 |
體內研究(In Vivo) | ||
體內研究活性 | Wortmannin劑量為1mg/kg可抑移植瘤小鼠中SW1990的腹膜轉移,無重量損失。[10] Wortmannin抑制在小鼠正常組織(肺,心臟和腦組織勻漿)及腫瘤組織中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在劑量為0.7 mg/kg時無死亡或急性毒性。與gemcitabine聯(lián)合使用時,可大大增加細胞凋亡和抑制原位腫瘤生長,兩種藥物單獨使用都無以上效果。[11] |
|
---|---|---|
動物實驗 | Animal Models | 人胰腺癌細胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。 |
Dosages | 0.175, 0.35, 和0.7 mg/kg | |
Administration | 靜脈注射 |
分子量 | 428.43 | 分子式 | C23H24O8 |
CAS號 | 19545-26-7 | SDF | Download Wortmannin SDF |
Smiles | CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 85 mg/mL ( (198.39 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 |
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項